Cyclacel Pharmaceuticals Stock Net Income
| CYCC Stock | USD 0.36 0.01 2.86% |
Cyclacel Pharmaceuticals fundamentals help investors to digest information that contributes to Cyclacel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cyclacel Stock. The fundamental analysis module provides a way to measure Cyclacel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclacel Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -22.6 M | -23.7 M | |
| Net Loss | -24.7 M | -23.5 M | |
| Net Loss | -24.6 M | -25.8 M | |
| Net Loss | (26.51) | (27.84) | |
| Net Income Per E B T | 0.88 | 1.01 |
Cyclacel | Net Income |
Cyclacel Pharmaceuticals Company Net Income Analysis
Cyclacel Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cyclacel Pharmaceuticals Net Income | (22.55 M) |
Most of Cyclacel Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclacel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cyclacel Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclacel Pharmaceuticals is extremely important. It helps to project a fair market value of Cyclacel Stock properly, considering its historical fundamentals such as Net Income. Since Cyclacel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclacel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclacel Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cyclacel Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cyclacel Pharmaceuticals reported net income of (22.55 Million). This is 106.61% lower than that of the Biotechnology sector and 132.2% lower than that of the Health Care industry. The net income for all United States stocks is 103.95% higher than that of the company.
Cyclacel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclacel Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclacel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics of similar companies.Cyclacel Pharmaceuticals is currently under evaluation in net income category among its peers.
Cyclacel Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Cyclacel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclacel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclacel Pharmaceuticals' value.| Shares | Signaturefd, Llc | 2024-09-30 | 20.0 | Harbour Investments, Inc. | 2024-06-30 | 13.0 | Bank Of America Corp | 2024-06-30 | 10.0 | Qube Research & Technologies | 2024-06-30 | 3.0 | Acadian Asset Management Llc | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 134 K | Ubs Group Ag | 2024-06-30 | 38 K | Point72 Asset Management, L.p. | 2024-06-30 | 15.3 K | Citadel Advisors Llc | 2024-06-30 | 12.3 K | Hrt Financial Llc | 2024-06-30 | 10.7 K |
Cyclacel Fundamentals
| Return On Equity | -5.71 | ||||
| Return On Asset | -1.03 | ||||
| Operating Margin | (911.00) % | ||||
| Current Valuation | (743.76 K) | ||||
| Shares Outstanding | 6.29 M | ||||
| Shares Owned By Insiders | 4.81 % | ||||
| Shares Owned By Institutions | 18.02 % | ||||
| Number Of Shares Shorted | 66.77 K | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 27.98 X | ||||
| Revenue | 420 K | ||||
| Gross Profit | (455 K) | ||||
| EBITDA | (25.42 M) | ||||
| Net Income | (22.55 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 37 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.38 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (16.11 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (27.40) X | ||||
| Target Price | 1.0 | ||||
| Beta | 0.56 | ||||
| Market Capitalization | 2.24 M | ||||
| Total Asset | 8.8 M | ||||
| Retained Earnings | (428.28 M) | ||||
| Working Capital | (717 K) | ||||
| Current Asset | 24.57 M | ||||
| Current Liabilities | 5.75 M | ||||
| Net Asset | 8.8 M |
About Cyclacel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclacel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclacel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Cyclacel Pharmaceuticals Piotroski F Score and Cyclacel Pharmaceuticals Altman Z Score analysis. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.